Opinion

Video

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
X-ray. ofheart -- Image credit: Anusorn | stock.adobe.com
December 13th 2024

FDA Expands Indication for Impella Heart Pumps to Include Pediatric Patients

Gillian McGovern, Assistant Editor
GLP1 Agonists and Dietary Fiber May Reduce VTE Risk and Improve GVHD Outcomes
December 7th 2024

GLP1 Agonists and Dietary Fiber May Reduce VTE Risk and Improve GVHD Outcomes

Alana Hippensteele, Managing Editor
Block letters spelling POTS | Image Credit: © Fauzi - stock.adobe.com
December 3rd 2024

Patients With Post-COVID POTS Experience Disruptions in Circadian Blood Pressure Rhythm Regulation

Alexandra Gerlach, Associate Editor
Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events
December 2nd 2024

Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events

Stuart Long
Aprocitentan: A New Hope in Resistant Hypertension Management
November 27th 2024

Aprocitentan: A New Hope in Resistant Hypertension Management

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS
Cardiovascular Health, Atrial Fibrillation, FDA Approval | Image Credit: Sebastian Kaulitzki | stock.adobe.com
Published: November 27th 2024 | Updated: November 27th 2024

FDA Approves Landiolol For Treatment of Supraventricular Tachycardia

Ashley Gallagher, Associate Editor